Leila Akkari

Leila Akkari

Auto-generated profile, based on publicly available information

Leila Akkari

Division of Tumor Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2013 in Nature Medicine
Verified
Journal Article
Open access
PDF file
SPStephanie M Pyonteck
Stephanie M Pyonteck
LALeila Akkari
Leila Akkari
ASAlberto J. Schuhmacher
Alberto J. Schuhmacher
RBRobert L Bowman
Robert L Bowman
LSLisa Sevenich
Lisa Sevenich
JJJohanna A Joyce
Johanna A Joyce
The authors provide preclinical testing of a CSFR-1 inhibitor in proneural glioma models. The compound targets macrophages in the tumor microenvironment rather than tumor cells themselves and is shown to portend considerable antitumor effects. Its activity relies on re-education of tumor-associated macrophages without affecting their survival, reverting their tumor-promoting phenotype. Moreover, gene signatures capturing the tumorigenic features of macrophages can predict survival in human patients with glioma, underscoring the potential relevance of this strategy as a glioma therapy. Glioblastoma multiforme (GBM) comprises several molecular subtypes, including proneural GBM. Most therapeutic approaches targeting glioma cells have failed. An alternative strategy is to target cells in the glioma microenvironment, such as tumor-associated macrophages and microglia (TAMs). Macrophages depend on colony stimulating factor-1 (CSF-1) for differentiation and survival. We used an inhibitor of the CSF-1 receptor (CSF-1R) to target TAMs in a mouse proneural GBM model, which significantly increased survival and regressed established tumors. CSF-1R blockade additionally slowed intracranial growth of patient-derived glioma xenografts. Surprisingly, TAMs were not depleted in treated mice. Instead, glioma-secreted factors, including granulocyte-macrophage CSF (GM-CSF) and interferon-γ (IFN-γ), facilitated TAM survival in the context of CSF-1R inhibition. Expression of alternatively activated M2 markers decreased in surviving TAMs, which is consistent with impaired tumor-promoting functions. These gene signatures were associated with enhanced survival in patients with proneural GBM. Our results identify TAMs as a promising therapeutic target for proneural gliomas and establish the translational potential of CSF-1R inhibition for GBM.

1 April 2013 in Cell
Verified
Journal Article
Closed access
ALAmaia Lujambio
Amaia Lujambio
LALeila Akkari
Leila Akkari
JSJanelle Simon
Janelle Simon
DGDanielle Grace
Danielle Grace
DTDarjus F. Tschaharganeh
Darjus F. Tschaharganeh
SLScott W. Lowe
Scott W. Lowe

20 May 2016 in Science
Verified
Journal Article
Closed access
PDF file
DQDaniela F. Quail
Daniela F. Quail
RBRobert L. Bowman
Robert L. Bowman
LALeila Akkari
Leila Akkari
MQMarsha L. Quick
Marsha L. Quick
ASAlberto J. Schuhmacher
Alberto J. Schuhmacher
JJJohanna A. Joyce
Johanna A. Joyce
Another pathway to cancer resistance: Therapies targeting the tumor microenvironment show promise for treating cancer. For example, antibodies targeting colony-stimulating factor-1 receptor (CSF-1R) inhibit protumorigenic macrophages and regress tumors in mouse models of glioblastoma multiforme (GBM), a deadly form of brain cancer. Quail et al. found that although CSR-1R blockade prolonged survival in mouse models of GBM, more than 50% of tumors eventually recurred. Recurrence was correlated with elevated PI3-K activity in tumors, driven by macrophage-secreted IGF-1. Blocking PI3-K and IGF-1 signaling in rebounding tumors prolonged survival. Thus, tumors can acquire resistance to therapy through intrinsic changes and through changes in their microenvironment. Science , this issue p. 10.1126/science.aad3018

1 November 2016 in Cell Reports
Verified
Journal Article
Open access
RBRobert L. Bowman
Robert L. Bowman
FKFlorian Klemm
Florian Klemm
LALeila Akkari
Leila Akkari
SPStephanie M. Pyonteck
Stephanie M. Pyonteck
LSLisa Sevenich
Lisa Sevenich
JJJohanna A. Joyce
Johanna A. Joyce
Extensive transcriptional and ontogenetic diversity exists among normal tissue-resident macrophages, with unique transcriptional profiles endowing the cells with tissue-specific functions. However, it is unknown whether the origins of different macrophage populations affect their roles in malignancy. Given potential artifacts associated with irradiation-based lineage tracing, it remains unclear if bone-marrow-derived macrophages (BMDMs) are present in tumors of the brain, a tissue with no homeostatic involvement of BMDMs. Here, we employed multiple models of murine brain malignancy and genetic lineage tracing to demonstrate that BMDMs are abundant in primary and metastatic brain tumors. Our data indicate that distinct transcriptional networks in brain-resident microglia and recruited BMDMs are associated with tumor-mediated education yet are also influenced by chromatin landscapes established before tumor initiation. Furthermore, we demonstrate that microglia specifically repress Itga4 (CD49D), enabling its utility as a discriminatory marker between microglia and BMDMs in primary and metastatic disease in mouse and human.

21 July 2021 in Nature
Verified
Journal Article
Closed access
HJHaojie Jin
Haojie Jin
YSYaoping Shi
Yaoping Shi
YLYuanyuan Lv
Yuanyuan Lv
SYShengxian Yuan
Shengxian Yuan
CRChristel F. A. Ramirez
Christel F. A. Ramirez
RBRené Bernards
René Bernards

15 March 2023 in Cell
Verified
Journal Article
Closed access
DKDaan J. Kloosterman
Daan J. Kloosterman
LALeila Akkari
Leila Akkari